Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

Also called NCT03449199

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
Teijin America, Inc. (from the registry)
Registry
  • NCT NCT03449199
Other papers using this trial's data
  • A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial Kidney360, 2021-08-26 DOI, PubMed 35369650, PMC8676384 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03449199. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-10 (actual); primary completion 2019-05-07 (actual). Results posted on 2022-08-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
Condition
Diabetic Kidney Disease
Intervention (Drug)
TMX-049
Intervention (Drug)
Placebo
Lead sponsor
Teijin America, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03449199
Content hash
a585660d577360f739d2b16aed485bd69150089f9f65bb10b9f59a9cd1e0b459